Epigenetics, disease, and therapeutic interventions

被引：73

作者：

Lu, Q.

Qiu, X.

Hu, N.

Wen, H.

Su, Y.

Richardson, B. C.

机构：

[1] Cent S Univ, Dept Dermatol, Xiangya Hosp 2, Hunan 410011, Peoples R China

[2] Cent S Univ, Epigenet Res Ctr, Xiangya Hosp 2, Hunan 410011, Peoples R China

[3] Univ Michigan, Dept Med, Vet Adm Med Ctr, Ann Arbor, MI 48109 USA

来源：

AGEING RESEARCH REVIEWS | 2006年 / 5卷 / 04期

关键词：

aging; epigenetics; cancer; autoimmunity; therapy;

D O I：

10.1016/j.arr.2006.07.001

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Heritable changes in gene expression that do not involve coding sequence modifications are referred to as "epigenetic". Epigenetic mechanisms principally include DNA methylation and a variety of histone modifications, of which the best characterized is acetylation. DNA hypermethylation and histone hypoacetylation are hallmarks of gene silencing, while DNA hypomethylation and acetylated histones promote active transcription. Aberrant DNA methylation and histone acetylation have been linked to a number of age related disorders including cancer, autoimmune disorders and others. Since epigenetic alterations are reversible, modifying epigenetic marks contributing to disease development may provide an approach to designing new therapies. Herein we review the role of epigenctic changes in disease development, and recent advances in the therapeutic modification of epigenetic marks. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

引用

页码：449 / 467

页数：19

共 131 条

[1] The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer [J].